Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial
Arcellx, Inc.
Arcellx Inc. (ACLX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,036,527 | $199,955,303 | 3.37% | |
| 2. | Vestal Point Capital Ryan Wilder | 2,750,000 | $181,087,500 | +16% | 9.53% |
| 3. | Perceptive Advisors Joseph Edelman | 2,478,000 | $163,176,300 | -16% | 6.05% |
| 4. | SR One Capital Simeon George | 2,346,630 | $154,525,586 | 33.49% | |
| 5. | Cormorant Asset Management Bihua Chen | 800,000 | $52,680,000 | -24% | 3.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 312,500 | $5,000,000.00 | 6,745,262 | 2022-06-21 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing | |
| $15.00 | 66,667 | $1,000,005.00 | 3,466,811 | 2022-02-08 | Filing | |
| $15.00 | 1,583,333 | $23,749,995.00 | 6,432,762 | 2022-02-08 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.04 | 5,364 | $488,315.49 | 8,466 | 2025-10-15 | Filing | |
| $86.22 | 1,064 | $91,733.29 | 13,830 | 2025-10-06 | Filing | |
| $86.00 | 4,882 | $419,869.58 | 14,894 | 2025-10-03 | Filing | |
| $82.20 | 1,530 | $125,762.94 | 624 | 2025-09-30 | Filing | |
| $81.46 | 14,204 | $1,157,035.11 | 2,154 | 2025-09-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 247,408 | $20,312,197 | 0.02% | |
| 2. | 25,302 | $2,077,294 | 0.01% | |
| 3. | 3,100 | $254,510 | 0% | |
| 4. | 1,219 | $100,080 | 0% | |
| 5. | 370 | $30,377 | 0% |
News See All
11 Best Cancer Stocks to Buy Right Now
Cancer remains the second leading cause of death globally, after heart disease.
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Here’s Why Arcellx (ACLX) Declined in Q1
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
Billionaire Stanley Druckenmiller's Top 10 Stocks Picks with Huge Upside Potential
Wall Street is overflowing with data. If companies are not releasing their earnings, economic data flows almost daily.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Is Arcellx (ACLX) Poised to Capture Significant Market Share?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
Arcellx (ACLX) Surged in Q3. Here’s Why
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Here’s Why Arcellx (ACLX) Slipped in Q2
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
